Research ArticleOpen AccessGoogle Scholar indexed
Asian Case of Metastatic Melanoma in Which a Complete Response Was Maintained after Discontinuation of Dabrafenib and Trametinib
Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
- 1 Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
- 2 Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
- 3 Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
- 4 Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
- 5 Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
- 6 Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
- 7 Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
- 8 Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
Journal of Cosmetics, Dermatological Sciences and Applications·Volume 10 (2020)·Pages 55–58·Published 30 March 2020·DOI10.4236/jcdsa.2020.102006
Copy link · social · email
Abstract
A 54-year-old man diagnosed with metastatic melanoma of the right inguinal node with occult primary developed liver and bone metastases. The combination of dabrafenib plus trametinib was initiated, and a complete response (CR) was achieved 24 months after starting treatment. One month later, the target therapy was discontinued at the patient’s decision, and he has remained free from progression for 21 months since discontinuation. To the extent of our knowledge, real-world data in Asian melanoma concerning the discontinuation of dabrafenib plus trametinib after achieving CR have not been published; therefore, our case is a meaningful one for considering to cease target drugs and to rescue their financial toxicity.
KeywordsMetastatic MelanomaDabrafenibTrametinibComplete ResponseDiscontinuation
- Robert, C., Grob, J.J., Stroyakovskiy, D., et al. (2019) Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England Journal of Medicine, 381, 626-636. https://doi.org/10.1056/NEJMoa1904059
- Tolk, H., Satzger, I., Mohr, P., et al. (2015) Complete Remission of Metastatic Melanoma upon BRAF Inhibitor Treatment—What Happens after Discontinuation? Melanoma Research, 25, 362-366. https://doi.org/10.1097/CMR.0000000000000169
- Desvignes, C., Abi Rached, H., Templier, C., et al. (2017) BRAF Inhibitor Discontinuation and Rechallenge in Advanced Melanoma Patients with a Complete Initial Treatment Response. Melanoma Research, 27, 281-287. ttps://doi.org/10.1097/CMR.0000000000000350
- Vanhaecke, C., Deilhes, F., Chanal, J., et al. (2017) BRAF V600 Inhibitor Discontinuation after Complete Response in Advanced Melanoma: A Retrospective Analysis of 16 Patients. British Journal of Dermatology, 177, 94-95. https://doi.org/10.1111/bjd.15345
- Carlino, M.S., Vanella, V., Girgis, C., et al. (2016) Cessation of Targeted Therapy after a Complete Response in BRAF-Mutant Advanced Melanoma: A Case Series. British Journal of Cancer, 115, 1280-1284. https://doi.org/10.1038/bjc.2016.321
- Brugnara, S., Sicher, M., Bonandini, E.M., et al. (2018) Treatment with Combined Dabrafenib and Trametinib in BRAFV600E-Mutated Metastatic Malignant Melanoma: A Case of Long-Term Complete Response after Treatment Cessation. Drug in Context, 7, 212515. https://doi.org/10.7573/dic.212515